MIVI Neuroscience Presents Primary Endpoint Results from the EvaQ Trial — at the 2024 International Stroke Conference

Primary effectiveness endpoint results show high revascularization rates of 93.9% mTICI 2b/3

Related Keywords

United States ,France ,Bob Colloton ,Neuroscience Inc ,National Institutes Of Health Stroke Scale ,Clinical Events Committee ,International Stroke Conference ,Evaq Trial ,Revascularization System ,Stroke Conference ,Large Vessel Occlusion ,Guide Catheter ,Flow Tubing ,National Institutes ,Health Stroke Scale ,Clinical Events ,Global Primary Investigators ,